Patents by Inventor James Warburton

James Warburton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210340242
    Abstract: A method is provided for reducing the treatment burden for patients who have an intraocular neovascular disorder, the method comprising administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and/or 12 weeks.
    Type: Application
    Filed: July 16, 2021
    Publication date: November 4, 2021
    Inventors: Margarita Gekkieva, Peter Sallstig, Werner Schmidt, James Warburton, Andreas Weichselberger
  • Patent number: 11098110
    Abstract: A method is provided for reducing the treatment burden for patients who have an intraocular neovascular disorder, the method comprising administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and/or 12 weeks.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: August 24, 2021
    Assignee: NOVARTIS AG
    Inventors: Margarita Gekkieva, Peter Sallstig, Werner Schmidt, James Warburton, Andreas Weichselberger
  • Publication number: 20210017266
    Abstract: A method is provided for treating a patient having a neovascular ocular disease.
    Type: Application
    Filed: March 8, 2019
    Publication date: January 21, 2021
    Inventors: Amy RACINE, James WARBURTON, Andreas WEICHSELBERGER
  • Publication number: 20180298092
    Abstract: A method is provided for reducing the treatment burden for patients who have an intraocular neovascular disorder, the method comprising administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and/or 12 weeks.
    Type: Application
    Filed: June 26, 2018
    Publication date: October 18, 2018
    Applicant: Novartis AG
    Inventors: Margarita Gekkieva, Peter Sallstig, Werner Schmidt, James Warburton, Andreas Weichselberger
  • Patent number: 10035850
    Abstract: A method is provided for reducing the treatment burden for patients who have an intraocular neovascular disorder, the method comprising administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and/or 12 weeks.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: July 31, 2018
    Assignee: Novartis Pharma AG
    Inventors: Margarita Gekkieva, Peter Sallstig, Werner Schmidt, James Warburton, Andreas Weichselberger
  • Publication number: 20160130337
    Abstract: A method is provided for reducing the treatment burden for patients who have an intraocular neovascular disorder, the method comprising administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and/or 12 weeks.
    Type: Application
    Filed: November 6, 2015
    Publication date: May 12, 2016
    Inventors: Margarita Gekkieva, Peter Sallstig, Werner Schmidt, James Warburton, Andreas Weichselberger
  • Publication number: 20080293565
    Abstract: An odor control product is disclosed comprising an activated carbon impregnated with a metal oxide and a salt, wherein the carbon has an activity high enough to compensate for the physical adsorption capacity used by the salt. Methods of making metal-impregnated activated carbon using water-soluble metal salts are provided without need for ammoniacal solvent media. An activated carbon base of higher activity than would be normally employed is impregnated with water-soluble metal salt. The impregnated carbon is impregnated with an aqueous alkaline solution and the resulting hydroxide decomposed to the metal oxide.
    Type: Application
    Filed: May 23, 2008
    Publication date: November 27, 2008
    Applicant: Calgon Carbon Corporation
    Inventor: Andrew James Warburton
  • Patent number: 5704115
    Abstract: A self-closing main distributing frame of any shape, (e.g. rectangular) which increases its capacity by growth in the vertical direction. The frame includes a stack of self-closing horizontal planes, or shelves, open to the outer face, and supported by brackets attached to vertical members on the interior face.
    Type: Grant
    Filed: May 8, 1995
    Date of Patent: January 6, 1998
    Inventor: Kenneth James Warburton